Module

Treatment of Advanced or Hormone-Refractory Disease

Source: Proceedings of the 17th International Prostate Cancer Update Meeting

Treatment of Advanced or Hormone-Refractory Disease

Faculty:
Nicholas J. Vogelzang, MD

CME CREDIT INFORMATION

Release Date: 06/28/07

Expiration Date: 06/27/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss first- and second-line treatment strategies for advanced or hormone-refractory prostate cancer patients
Describe immunotherapy approaches for treating advanced prostate cancer patients
Summarize clinical trial data on new hormonal agents for treating advanced or hormone-refractory patients

Topics covered include:

Introduction
Case 1: A Hormone- and Chemotherapy-Responsive Patient
Patient Chooses Combined Androgen Blockade
First- and Second-Line Hormonal Therapies
Immune Therapy in Prostate Cancer
Other Immunotherapy Approaches
First-Line Chemotherapy for Metastatic Prostate Cancer Patients
Pivotal Docetaxel HRPC Trials
Case 2: Management of a Chemotherapy-Refractory Patient
Second-Line Chemotherapy
Satraplatin
Deacetylase Inhibitors and New Hormonal Agents

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.